SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Bristol-Myers (BMY)

BMY RSS Feed
Add BMY Price Alert      Hide Sticky   Hide Intro
Moderator: DewDiligence
Search This Board: 
Last Post: 12/14/2017 7:56:21 PM - Followers: 35 - Board type: Free - Posts Today: 0
SureTrader
Interactive Brokers Advertisement
BMY
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BMY News: Bristol-Myers Squibb Granted Exclusive License by Ono Pharmaceutical for Multiple Programs Targeting Immuno-Suppressive Facto... 12/13/2017 06:30:00 PM
BMY News: U.S. Food & Drug Administration (FDA) Accepts Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilim... 12/13/2017 05:28:00 PM
BMY News: Seattle Genetics & Bristol-Myers Squibb Highlight Interim Results from Phase 1/2 Study Evaluating the Combination of ADCETRIS... 12/11/2017 10:30:00 AM
BMY News: Sprycel (dasatinib) Added to Standard Chemotherapy Demonstrates Three-Year Survival Benefit in Pediatric Patients with Newly ... 12/09/2017 09:30:00 AM
BMY News: Bristol-Myers Squibb Announces Dividend Increase 12/07/2017 04:15:00 PM
PostSubject
#678  Sticky Note BMY’s 3Q17 PR: DewDiligence 10/26/17 11:21:07 AM
#713   Sabby Management has a ton of BMY, as Johnny_C 12/14/17 07:56:20 PM
#712   No, and more calls expiring worthless tomorrow. Johnny_C 12/14/17 08:29:42 AM
#711   PDUFA date for Opdivo/Yervoy in first-line RCC is DewDiligence 12/13/17 07:47:03 PM
#710   The small dividend increase doesn't say anything in DewDiligence 12/08/17 08:52:22 AM
#709   Might be wrong but that doesn’t seem to Johnny_C 12/07/17 10:47:29 PM
#708   BMY increases annualized dividend to $1.60 (from $1.56): DewDiligence 12/07/17 05:39:10 PM
#707   Intersting, according to latest interview by BMY they Johnny_C 12/07/17 11:55:00 AM
#706   Yes, it is, especially for cancer treatments. DewDiligence 12/06/17 10:23:59 AM
#705   China market is huge! Johnny_C 12/06/17 10:19:03 AM
#704   Breakthrough on HIV? Opdivo the cure? Stock Barber 12/01/17 12:46:50 PM
#703   Opdivo shows OS benefit in Chinese NSCLC second-line patients: DewDiligence 11/30/17 07:21:28 PM
#702   It's going to the trash can rather than DewDiligence 11/22/17 03:12:31 PM
#701   Sure doesn't bode well. Looks like the pps chmcnfunds 11/22/17 03:09:02 PM
#700   (IPH.PA)—BMY licensed program bites the dust: #msg-136389492. DewDiligence 11/22/17 12:23:41 PM
#699   Hmmm. Looks like non of the Johnny_C 11/20/17 05:20:55 PM
#698   The BD comments were interesting. I am going Johnny_C 11/16/17 08:58:28 PM
#697   Very good presentation by John Elicker, who must DewDiligence 11/15/17 03:52:01 PM
#696   Seeking Alpha transcript! https://seekingalpha.com/article/4125170-bristol-mye Johnny_C 11/15/17 03:51:06 PM
#695   Interesting trading.... mostly all red except Pfe Johnny_C 11/14/17 11:16:57 PM
#694   Interesting choice naming COO. Very experienced in oncology Johnny_C 11/14/17 07:16:41 AM
#693   Yes and no. Clinical trials very Johnny_C 11/13/17 01:05:36 PM
#692   Oncology can't be anywhere near 50% of PFE's DewDiligence 11/13/17 10:59:35 AM
#691   COO named at PFE after a very long Johnny_C 11/13/17 10:23:39 AM
#690   https://seekingalpha.com/article/4124190-bristol-myers-squibb-brings-ace-card-mi Inoviorulez 11/13/17 09:20:52 AM
#689   Nice, here we go again. Big move up Johnny_C 11/08/17 03:52:16 PM
#688   BMY presents OS data from successful CHECKPOINT-214 study DewDiligence 11/07/17 11:31:45 AM
#687   Tony, if in fact they are a buy Johnny_C 11/06/17 10:06:20 AM
#686   Hey Tony, this is quite elaborate. mbenson898 11/02/17 09:52:36 AM
#685   BMY Q3 ANALYSIS Tonymann 11/02/17 08:48:23 AM
#684   My guess heading back up and 62.5 Options Johnny_C 10/31/17 01:25:22 PM
#683   BMY—Some bad writing from Bloomberg: Johnny_C 10/29/17 12:05:51 PM
#682   MRK's after-hours press release on Keytruda: #msg-135760504. DewDiligence 10/28/17 11:26:15 AM
#681   Massive A/H trading on Merc announcement. Opdivo looking Johnny_C 10/28/17 06:29:07 AM
#680   Transcript of BMY’s 3Q17 CC: DewDiligence 10/27/17 04:06:31 PM
#679   This sell off is great. Low Johnny_C 10/27/17 01:54:24 PM
#678   BMY’s 3Q17 PR: DewDiligence 10/26/17 11:21:07 AM
#677   Bristol-Myers Squibb (BMY) Q3 results: Revenues: $5,254M (+6.7%); Johnny_C 10/26/17 10:32:49 AM
#676   This is awesome. Hopefully will bring Options Johnny_C 10/26/17 10:31:00 AM
#675   Good buying opp. Loading up on January’s Johnny_C 10/26/17 10:01:51 AM
#674   Looks like PFE not waiting until 2018 to Johnny_C 10/26/17 07:33:38 AM
#673   Agrrrr. The October 70’s Johnny_C 10/25/17 04:47:41 PM
#672   I thought it was a little high myself, Johnny_C 10/16/17 10:23:19 AM
#671   I don't doubt that Eliquis will attain $7B DewDiligence 10/16/17 10:08:51 AM
#670   Lost internet on last message, but friend thinks Johnny_C 10/16/17 10:00:27 AM
#669   I think so to. A friend is pretty Johnny_C 10/16/17 08:47:27 AM
#668   The $4B figure is preposterous, IMO. DewDiligence 10/14/17 12:29:05 PM
#667   CNBC -- $4 billion dollars in synergies? Johnny_C 10/14/17 09:49:12 AM
#666   Should help all big pharma; https://www.google.com/amp/m.scmp.com/news/china/po Johnny_C 10/13/17 04:09:58 PM
#664   Options are work for sure, especially when they Johnny_C 10/13/17 10:59:17 AM
#663   I don't mess with options. I find it's DewDiligence 10/13/17 10:45:53 AM
PostSubject